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PCASE7
INCLUDING A PHARMACOECONOMIC MODEL IN THE
FORMULARY REVIEW PROCESS OF NEW
Grossomanides J1, Possidente C2
1Blue Cross Blue Shield of Vermont, Berlin,VT, USA, 2Pﬁzer, Jericho
Center,VT, USA
Organization: Blue Cross Blue Shield of Vermont
Problem or Issue Addressed: Approval of new prescription prod-
ucts by the Federal Drug Administration dictates that organiza-
tions review the medication and consider the drug’s position on
the formulary. Pharmacy and Therapeutics Committee members
are required to consider many factor.
Goals: Utilize a pharmacoeconomic model to evaluate the impact
of pregabalin per member per month (PMPM) costs and incor-
porate this information into the formulary review process to
determine the appropriate formulary status of pregabalin.
Outcomes items used in the decision: Per member per month
(PMPM) costs, and the organization’s drug costs and utilization
patterns of selected agents for epilepsy and neuropathic pain
were reviewed.
Implementation Strategy: Drug utilization data for all second
generation antiepileptic drugs and medications commonly used
to treat neuropathic pain were reviewed. The drug costs per day
and the number patients prescribed each drug were collected
monthly. Total drug costs and PMPM costs were calculated for
each month between September 2005 and November 2006 using
Therapy Cost GPS. Therapy Cost GPS is an analytical software
tool, developed by Pﬁzer, Inc. that supports the development of
cost models to assess the ﬁnancial impact of formulary changes
before they are established and accurately evaluates their impact
once they have been implemented. The results were compared to
the same parameters from August 2005, which served as a base-
line before pregabalin was available. The available results were
included with the pregabalin formulary presentation to the Phar-
macy and Therapeutics Committee in April 2006, with the com-
mitment for continual evaluation.
Results: A total of 6259 patients received drugs targeted for
analysis in August 2005, accounting for $1,829,626 in total drug
costs, and a PMPM cost of $1.02. In November 2006 after 15
months, 5825 patients received drugs targeted for analysis, and
total drug costs decreased by 7.2% to $1,698,187. The PMPM
cost was reduced to $0.94, a reduction independent of patient
number. During November 2006 pregabalin prescribing was
limited, accounting for approximately 2% utilization of com-
parator drugs. Mean (+/− SD) monthly values during the 15-
month data collection period for number patients, total drug
costs and PMPM cost were; 5761 (326), $1,726,090 ($42,008),
$0.96 ($0.02), respectively. The data suggests pregabalin usage
and PMPM costs are projected to remain stable. Shifting drug
utilization patterns and reductions in the cost of generic
gabapentin likely accounted for the reduced PMPM cost.
Because pregabalin utilization was limited and did not increase
the PMPM costs, it was decided to continue the drug’s position
as an unrestricted third tier agent, without the need to imple-
ment a step edit or prior authorization requirement.
Lessons Learned: Because utilization of pregabalin during the
ﬁrst year has been limited, it is unclear if the ﬁnancial implica-
tions will change over time. Ongoing evaluation will be con-
ducted to further assess pregabalin utilization patterns and
determine if increased utilization is observed and if formulary
adjustments are required. Patient diagnosis was not available so
the indication for pregabalin was not included in the review.
Other organizations with access to linked pharmacy and medical
databases could reﬁne the review process by focusing on drug
therapy for a speciﬁc indication. The monthly monitoring of
drug utilization patterns and costs provides helpful information
to evaluate the formulary position of newly available drugs, and
allows a concurrent review of existing therapies. Changes in
generic drug usage, cost reductions associated with shifts from
single source to multi-source generic products, and increased
costs of branded products are examples of changes readily
observed with an ongoing review process. As a result of this
project, cost models will be integrated into the formulary review
process as additional new drugs become available. In addition,
future plans include using a similar cost model to evaluate estab-
lished drugs and drug class reviews.
PCASE8
POLYPHARMACY MEDICATION THERAPY MANAGEMENT
PROGRAM (MTMP) CASE STUDY
Miller SA, Mu Y, Lou Y, Huang Z, Radzicki R, Cozzi G, Heath P,
Sekula R, Lee KK
Walgreens Health Services, Deerﬁeld, IL, USA
Organization: Walgreens Health Services
Problem or Issue Addressed: Approximately one-third of the
elderly population is at risk for polypharmacy and its complica-
tion. Polypharmacy increases patients’ risks for many ill effects,
including drug interactions, non-adherence, hospitalizations,
morbidity and mortality.
Goals: The WHS Polypharmacy MTMP is designed to ensure
optimum therapeutic, clinical and ﬁnancial outcomes by pro-
moting proper prescribing and improving patient medication
use. Three polypharmacy cases were examined to illustrate the
process of polypharmacy intervention process and how such
interventions may help reduce health care expenditures.
Outcomes items used in the decision: a) Drug therapy outcomes:
reduction in drug interactions and therapeutic duplications,
ensuring appropriateness of medication therapies and improved
compliance and persistency; b) Literature-based clinical out-
comes: reduction in the incidence and severity of adverse events
including falls and fractures, hospitalizations, nursing home
admissions, morbidity and mortality; c) Financial outcomes:
pharmacy and medical cost savings.
Implementation Strategy: 1) Identify polypharmacy MTMP can-
didates based on number of disease states, number of mainte-
nance medications and estimated yearly drug spend; 2) Enroll
polypharmacy MTMP candidates according to program speciﬁ-
cation (Opt-in or Opt-out model). 3) Review member medica-
tion proﬁles by pharmacists at the MTM clinical call center,
utilizing a Medication Appropriateness Index. 4) Contact the
prescribing physician to discuss the identiﬁed medication-related
issues and recommend possible therapeutic solutions. 5) Docu-
ment the results of the clinical intervention and fax/mail a copy
of the Medication Action Plan (MAP), Personal Medication
Record (PMR) and dosing calendar to the participant’s commu-
nity pharmacist and/or patient; 6) Counsel patient on therapy
changes and proper medication use. 7) Follow up on polyphar-
macy intervention outcomes.
Results: Case One: Ten medications were intervened upon by
MTM call center pharmacists after a patient’s medication history
was reviewed. Speciﬁc interventions accepted by the prescriber
included: combining multiple medications to a single medication
for the purpose of decreasing pill load; generic substitution to
reduce cost; reducing dosage to help ensure safe dosage in the
elderly; discontinuing duplicated medication. Assuming all med-
ications were maintenance medications and the patient would be
in full compliance with the recommended medications for the
next 12 months, the total pharmacy saving for this case would
be $4,413 per year.
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Case Two: Six medications were intervened upon by MTM call
center pharmacists after a patient’s medication history was
reviewed. Speciﬁc interventions accepted by the prescriber
included: combining multiple medications to a single medication
for the purpose of decreasing pill load and discontinuing med-
ication due to duplicate therapy. Assuming all medications were
maintenance medications and the patient would be in full com-
pliance with the recommended medications for the next 12
months, the total pharmacy saving for this case would be $1,019
per year.
Case Three: A patient was identiﬁed as HIV positive through drug
inference and conﬁrmed by the physician. MTM call center phar-
macists recommended adding an NRTI in accordance with
national guidelines. MTM pharmacists also noticed the patient
was noncompliant with his lipid lowering therapy, Tricor, and
recommended promoting proper use of this medication. The total
added drug cost from these recommendations would be $3,695
per year. However, incorporating the NRTI into the drug therapy
could result in $10,000 per year savings in medical cost in accor-
dance with literature. In this particular case, the net savings in
overall health care expenditures could be $6,305 per year.
Overall, the WHS polypharmacy MTMP identiﬁed 359,124
Medicare Part D members eligible for the program in 2006.
However, only about 5% of the qualiﬁed members were enrolled
in the program largely due to the chosen opt-in program design.
The WHS polypharmacy MTMP provided appropriate
therapy recommendations to the patients’ physicians, addressed
compliance and persistency issues, and optimized drug therapy.
Drug therapy outcomes have been improved by ensuring efﬁcacy
and minimizing toxicities through decreasing the number of drug
conﬂicts (e.g. drug interactions, duplicate therapy). According to
literature, clinical outcomes may be improved as a consequence
of this intervention. In addition to bringing better health out-
comes, the WHS polypharmacy MTMP could also reduce both
pharmacy and medical health care expenditures.
Lessons Learned: The WHS Polypharmacy MTMP participation
rates varied by the plan design. Overwhelmingly, those plans
with a polypharmacy MTMP opt-out design had a much higher
patient participation rate in comparison to plans with an opt-in
design (82.26% vs. 4.43%). Possible reasons for the low member
participation rate in the opt-in model include members having
difﬁculties understanding the beneﬁts and opt-in invitations
being discarded with the materials that members did not see as
pertinent.
PCASE9
MANAGEMENT OF INAPPROPRIATE USE OF 
GROWTH HORMONE
Jan SA,Valderma M
Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA
Organization: Horizon Blue Cross Blue Shield of New Jersey
Problem or Issue Addressed: Inappropriate use of growth
Hormone.
Goal: The goal of the program was to identify off label use of
growth hormone.
Outcomes items used in the decision: Pharmacy and medical data
with diagnosis was used for identiﬁcation.
Implementation Strategy: Members receiving growth hormone
were identiﬁed by using Pharmacy and medical claims data. The
physicians prescribing these members were also identiﬁed. com-
munications were sent to members and Physicians who did not
meet the FDA approved criteria or the diagnosis. Based on the
responses the next step was either disconitnuation or further
investigation.
Results: We identiﬁed 78 members who received growth hormone
in the ﬁrst quarter of 2006, letters were sent to 35 members who
met the criteria of inappropriate use. This resulted in 28 blocks
and based on that the yearly savings was approx. $400,000. This
also included identifying 17 prescribers who were not using
growth hormone according to FDA approved indication and were
refered to investigation department for reviews.
Conclusions/Lessons Learned: The program was very effective
in identifying a potential problem of inapprpriate utilization and
helped the organization both clinically and ﬁnancially. integra-
tion of pharamcy and medical data provided evidence to take
measures for inappropriate utilization.
PCASE10
SHOULD GENETIC TESTING BE USED TO GUIDE 
WARFARIN THERAPY?
Gudgeon J1,Williams M1,Anderson J1, Meckley L2,Veenstra DL2
1Intermountain Healthcare, Salt Lake City, UT, USA, 2University of
Washington, Seattle, WA, USA
Organization: Intermountain Healthcare, Salt Lake City.
Problem or Issue Addressed: Use of gene testing to guide war-
farin dosing.
Organization: This project is being undertaken at Intermountain
Healthcare, an integrated health care system based in Utah, coor-
dinated by its Clinical Genetics Institute (CGI), in collaboration
with researchers at the University of Washington.
Problem or Issue Addressed: Warfarin is an effective anticoagu-
lant but has signiﬁcant bleeding risk. Recently variants in two
genes, CYP2C9 and VKORC1, have been shown to have a sig-
niﬁcant impact on the pharmacokinetics and pharmacodynam-
ics of warfarin, accounting for signiﬁcant variability in effective
dose between individuals. Though determination of variants of
these genes, when performed in a timely manner, can be incor-
porated into the algorithm used to determine starting dose of
warfarin, it is not clear whether the additional resources required
provide meaningful clinical beneﬁt.
Goals: The CGI hopes to use this project as a pilot to introduce
clinically useful, cost-effective (CE) genetic testing into the Inter-
mountain system, as well as developing methods that can be used
to make coverage decisions by the system’s health plan. The
primary goal is to determine both the clinical and economic value
of adding testing for these genes into the warfarin dosing algo-
rithm, in the setting of a community-based hospital, in order to
inform decisions about the use and coverage of the testing. The
secondary goal is to use this pilot to help educate stakeholders
in the principles of cost effectiveness.
Outcomes items used in the decision: The primary endpoints are
the differences in the total cost of anticoagulation-related care,
the cost per adverse event avoided, and the cost per day within
therapeutic range.
Implementation Strategy: The intent is to use the results from the
cost effectiveness study in conjunction with the results of the clin-
ical trial, to bring the health plan decision makers together with
the delivery-side decision makers to make a coordinated deci-
sion, explicitly including local economic outcomes, about both
the use of and reimbursement for CYP2C9 and VKORC1 testing
in this setting. These efforts will be applied in the context of the
principles of process improvement and clinical decision support,
both integral parts of Intermountain’s culture, to ensure their
consistent and efﬁcient application.
Results: The study is currently underway.
Lessons Learned: Health plans will increasingly be required to
develop coverage and reimbursement policies for genetic tests,
which can present a complex balance of beneﬁts, risks, and costs.
Because sufﬁcient evidence for decision-making may not be avail-
